SAN CARLOS, Calif.--(BUSINESS WIRE)--Simpirica Spine Inc., developer of minimally invasive, flexion-restricting stabilization devices for the spine, has announced that it has appointed Milena Ridl as vice president of international sales and marketing. In the new role, Ridl will be responsible for expanding commercialization of the company’s LimiFlex™ Spinal Stabilization System internationally. The CE marked LimiFlex is a novel dynamic stabilization system designed to address flexion (forward bending) pain and instability without the need for spinal fusion.
“Milena is a talented, experienced medical technology executive with a deep and proven track record in spine,” said Austin Noll, president and chief executive officer of Simpirica Spine. “She joins Simpirica at an exciting time, as we are in an immediate position to greatly expand surgeon and patient access to the LimiFlex Spinal Stabilization System internationally.”
Ridl brings to Simpirica Spine more than 12 years of experience in medical technology sales and marketing, with significant focus in spine. She spent nearly five years of her career at Kyphon, where she held senior business development and European sales positions both before and after the company’s acquisition by Medtronic. She also served as director of European sales for SpineAlign Medical. Ridl joins Simpirica from biomaterials company MiMedx, where she was the vice president of sales for Europe, the Middle East and Africa.
“I believe the LimiFlex Stabilization System represents a major breakthrough that has the potential to greatly benefit surgeons, indicated patients and the healthcare system at large,” said Ridl. “I am very gratified to be part of the team bringing this important technology to the marketplace.”
Simpirica Spine developed the LimiFlex Spinal Stabilization System to provide patients affected by flexion pain and instability with a treatment alternative to spinal fusion. Multiple clinical studies have been conducted on the LimiFlex Spinal Stabilization System outside of the United States, with one-year follow-up data demonstrating significant reductions in disability and pain as well as segmental stability at the LimiFlex-stabilized level. The LimiFlex has been available commercially outside of the United States since January 2011. To date, hundreds of patients have been treated with the device.
In the United States, the LimiFlex Spinal Stabilization System is an investigational device and is limited by federal law to investigational use only.
About Simpirica Spine Inc.
Simpirica Spine was founded in 2006 to develop minimally invasive, flexion-restricting stabilization devices for the spine. The company’s lead product, the LimiFlex Spinal Stabilization System, is designed to address flexion (forward bending) pain and instability without the need for spinal fusion. LimiFlex is CE marked and available in markets outside of the United States, where it typically is used in conjunction with a surgical decompression for the treatment of lumbar spinal stenosis with or without degenerative spondylolisthesis. The LimiFlex Device provides spinal stabilization for patients who could benefit from additional stabilization in flexion. Simpirica Spine developed and tested its technology over a period of many years with the help of clinical and biomechanical experts from around the world. For more information, please visit www.simpirica.com.